Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Jul;14(7):863-8.
doi: 10.1128/CVI.00102-07. Epub 2007 May 9.

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England

Caroline Trotter  1 , Jamie Findlow, Paul Balmer, Ann Holland, Rita Barchha, Nick Hamer, Nick Andrews, Elizabeth Miller, Ray Borrow
Affiliations
Comparative Study

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England

Caroline Trotter et al. Clin Vaccine Immunol. 2007 Jul.

Abstract

Outer membrane vesicle (OMV) and recombinant protein-based vaccines targeted against multiple strains of group B meningococci are under development. The serum bactericidal antibody (SBA) assay has been designated the surrogate of protection, but the exact cutoff has not been determined. We measured the SBA titers in 2,415 serum samples and the anti-OMV IgG antibody concentrations in 2,672 serum samples representative of the English population to establish a baseline of natural immunity. SBA and anti-OMV IgG antibody titers are high in infants in the first 3 months of life, declining thereafter, presumably as maternal immunity wanes. About 6% of the subjects in the 1- to 11-year-old age group had SBA titers >or=4. During the teenage years, there was a marked increase in the percentage of subjects with SBA titers >or=4, rising to over 50% in 19-year-olds, with about 20% of older adults achieving this titer. The peak in SBA and anti-OMV IgG titers coincided with the peak in meningococcal carriage. Simple mathematical models confirm that the relationship between observed seroprevalence and carriage by age is consistent with carriage inducing SBA and that following an episode of carriage, SBA levels may remain elevated for many months. With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Percentage of sera with SBA titers ≥2, ≥4, and ≥8, by age.
FIG. 2.
FIG. 2.
Age-specific IgG OMV ELISA GMTs and 95% confidence intervals.
FIG. 3.
FIG. 3.
Age-specific incidence of serogroup B disease compared to the percentage of individuals with SBA titers ≥4.
FIG. 4.
FIG. 4.
Model fit to group B SBA and carriage data. This model assumes that the average duration of group B carriage is 6 months. Other parameters were estimated (Table 1). *, categories M (maternal immunity) and I (acquired immunity) are combined.
FIG. 5.
FIG. 5.
Age-specific seroprevalence of SBA antibodies to group B and group C reference strains in the United Kingdom.
See this image and copyright information in PMC

References

    1. Bennett, J. S., D. T. Griffiths, N. D. McCarthy, K. L. Sleeman, K. A. Jolley, D. W. Crook, and M. C. Maiden. 2005. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect. Immun. 732424-2432. - PMC - PubMed
    1. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Hoiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12970-976. - PMC - PubMed
    1. Borrow, R., G. M. Carlone, N. Rosenstein, M. Blake, I. Feavers, D. Martin, W. Zollinger, J. Robbins, I. Aaberge, D. M. Granoff, E. Miller, B. Plikaytis, L. van Alphen, J. Poolman, R. Rappuoli, L. Danzig, J. Hackell, B. Danve, M. Caulfield, S. Lambert, and D. Stephens. 2006. Neisseria meningitidis group B correlates of protection and assay standardization—international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 245093-5107. - PubMed
    1. Borrow, R., and E. Miller. 2006. Surrogates of protection, p. 323-341. In M. Frosch and M. C. Maiden (ed.), Handbook of meningococcal disease: infection biology, vaccination, clinical management. Wiley-VCH, Weinheim, Germany.
    1. Cartwright, K. A., J. M. Stuart, D. M. Jones, and N. D. Noah. 1987. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect 99591-601. - PMC - PubMed

Publication types

MeSH terms